Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: A disproportionality analysis of the US FDA adverse event reporting system database

Drug Safety

Volumn 35, Issue 4, 2012, Pages 315-323

  Motola, Domenico ^a   Piccinni, Carlo ^a   Biagi, Chiara ^a   Raschi, Emanuel ^a   Marra, Anna ^b   Marchesini, Giulio ^a   Poluzzi, Elisabetta ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Adverse drug reactions; Bone; Diabetes mellitus; Fracture; Myocardial infarction; Pioglitazone; Retinal oedema; Rosiglitazone; Thiazolidinediones

Indexed keywords

BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; INSULIN DERIVATIVE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE;

ADVERSE OUTCOME; ARTICLE; BONE INJURY; DIABETES MELLITUS; DRUG MARKETING; DRUG SAFETY; FRACTURE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART INFARCTION; HUMAN; JOINT INJURY; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RETINA MACULA EDEMA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BONE AND BONES; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; EYE; FEMALE; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; MACULAR EDEMA; MALE; META-ANALYSIS AS TOPIC; MYOCARDIAL INFARCTION; ODDS RATIO; RISK; THIAZOLIDINEDIONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84858782552     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11596510-000000000-00000     Document Type: Article

References (41)

1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71 (Pubitemid 46919772)
2. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189-95 (Pubitemid 47403105)
3. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170 (14): 1191-201
4. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-8 (Pubitemid 47403104)
5. Bilik D, McEwen LN, Brown MB, et al. Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD). Pharmacoepidemiol Drug Saf 2010; 19: 715-21
6. Bodmer M, Meier C, Kraenzlin ME, et al. Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf 2009; 32: 539-47
7. Dormuth CR, Carney G, Carleton B, et al. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009; 169: 1395-402
8. Douglas IJ, Evans SJ, Pocock S, et al. The risk of fractures associated with thiazolidinediones: a self-controlled caseseries study. PLoS Med 2009; 6: e1000154
9. Habib ZA, Havstad SL, Wells K, et al. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 592-600
10. Merante D, Menchini F, Truitt KE, et al. Diabetic macular edema: correlations with available diabetes therapies-evidence across a qualitative review of published literature from MEDLINE and EMBASE. Drug Saf 2010; 33: 643-52
11. Food and Drug Administration. FDA significantly restricts access to the diabetes drug Avandia [online]. Available from URL: http://www.fda.gov/Drugs/ DrugSafety/Post marketDrugSafetyInformationforPatientsandProviders/ucm 226956.htm [Accessed 2010 Oct 25]
12. European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim [online]. Available from URL: http://www. ema.europa.eu/docs/en-GB/document-library/Press-release/2010/09/ WC500096996.pdf [Accessed 2012 Feb 14]
13. Kessler DA. Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA 1993; 269: 2765-8 (Pubitemid 23154251)
14. Brown EG. Using MedDRA: implications for risk management. Drug Saf 2004; 27: 591-602 (Pubitemid 38822578)
15. US FDA. The Adverse Event Reporting System (AERS): latest quarterly data files [online]. Available from URL: http://www.fda.gov/Drugs/ GuidanceComplianceRegulatory Information/Surveillance/ucm082193 [Accessed 2012 Jan 20]
16. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2010 [online]. Available from URL: http://www.whocc.no/atc-ddd-index/[Accessed 2010Aug 30]
17. EUROMEDSTAT. EUROMEDSTAT: a project funded by the European Commission [online]. Available from URL: http://ec.europa.eu/health/ph-projects/2001/ monitoring/fp-monitoring-2001-frep-12-1-en.pdf [Accessed 2012 Feb 27]
18. Food and Drug Administration. Drugs FDA [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [Accessed 2010 Aug 30]
19. Egberts AC, Meyboom RH, van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf 2002; 25: 453-8 (Pubitemid 34729145)
20. Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 1997; 44: 513-8 (Pubitemid 27485484)
21. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009; 18: 427-36
22. Hauben M, Madigan D, Gerrits CM, et al. The role of data mining in pharmacovigilance. Expert Opin Drug Saf 2005; 4: 929-48 (Pubitemid 41246142)
23. Almenoff JS, Pattishall EN, Gibbs TG, et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 2007; 82: 157-66 (Pubitemid 47078877)
24. Centers for Disease Control and Prevention. Epi Info [online]. Available from URL: http://www.cdc.gov/epiinfo/[Accessed 2010 Aug 30]
25. Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf 2005; 28: 981-1007 (Pubitemid 41483705)
26. Ahmed I, Thiessard F, Miremont-Salame G, et al. Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study. Clin Pharmacol Ther 2010; 88: 492-8
27. van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 3-10 (Pubitemid 34269590)
28. Chen Yan, Guo JJ, Steinbuch M, et al. Comparison of sensitivity and timing of early signal detection of four frequently used signal detection methods: an empirical study based on the US FDA Adverse Event Reporting System Database. Pharm Med 2008; 22: 359-65
29. Food and Drug Administration. Reports received and reports entered into AERS by year [online]. Available from URL: http://www.fda.gov/Drugs/ GuidanceComplianceRe gulatoryInformation/Surveillance/AdverseDrugEffects/ucm 070434.htm [Accessed 2010 Aug 30]
30. Cohen A, Rabbani A, Shah N, et al. Changes in glitazone use among office-based physicians in the U.S., 2003-2009. Diabetes Care 2010; 33: 823-5
31. Shah ND, Montori VM, Krumholz HM, et al. Responding to an FDA warning: geographic variation in the use of rosiglitazone. N Engl J Med 2010; 363: 2081-4
32. Piccinni C, Motola D, Marchesini G, et al. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011; 34 (6): 1369-71
33. Willemen MJ, Mantel-Teeuwisse AK, Straus SM, et al. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011; 34: 369-74
34. Allegato I: riassunto delle caratteristiche del prodotto [online]. Available from URL: http://www.ema.europa.eu/docs/it-IT/document-library/EPAR- Product-Information/human/000285/WC500021386.pdf [Accessed 2012 Jan 20]
35. Hauben M, Patadia V, Gerrits C, et al. Data mining in pharmacovigilance: the need for a balanced perspective. Drug Saf 2005; 28: 835-42 (Pubitemid 41428541)
36. Hauben M, Reich L, DeMicco J, et al. 'Extreme duplication' in the US FDA Adverse Events Reporting System database. Drug Saf 2007; 30: 551-4 (Pubitemid 46873080)
37. Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004; 24: 743-9 (Pubitemid 38747859)
38. Pariente A, Gregoire F, Fourrier-Reglat A, et al. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 2007; 30: 891-8 (Pubitemid 47481444)
39. Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf 2007; 16: 359-65 (Pubitemid 46656857)
40. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203
41. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991; 10: 577-81